Surgery over watchful waiting better for younger prostate cancer patients
A new study in the New England Journal of Medicine finds that mortality rates are lower for younger men having surgery for prostate cancer, compared with those who follow watchful waiting.Prostate cancer is common among older men and rare in men under the age of 40.
Reliable pretreatment information assists prostate cancer patients in decision-making
Men who have been diagnosed with prostate cancer need to assimilate information rapidly in order to weigh the treatment options and make informed decisions.
How enzyme functions correlate with prostate cancer progression could lead to new treatments
A University of Houston (UH) scientist and his team are working to develop the next generation of prostate cancer therapies, which are targeted at metabolism.With approximately one out of six American men being diagnosed and nearly a quarter of a million new cases expected this year, prostate cancer is the most common malignancy among men in the U.S.
UCLA study finds robotic-assisted prostate surgery offers better cancer control
An observational study from UCLA's Jonsson Comprehensive Cancer comparing robotic-assisted prostate surgery to open surgery for prostate cancer found that patients who had robotic surgery had fewer instances of cancer cells at the edge of the surgical specimen, or fewer positive margins, and less need of additional cancer treatments, such as hormone therapy or radiation, than patients who had...
More intensive radiotherapy is better than less for localised prostate cancer
A radiotherapy regime involving higher doses of radiation is a better option than having lower doses for men with localised prostate cancer, the 10-year results of the largest trial of its kind have shown.
Research could help improve early diagnosis of prostate cancer
Prostate cancer patients could get better diagnosis and treatment for the disease in the future thanks to a successful research project at the University of Essex.Currently, is it difficult to distinguish between benign and aggressive malignant tumours, meaning some prostate cancer patients are unnecessarily "over-treated" which can lead to needless distress and anxiety.
Enzalutamide for metastatic prostate cancer: IQWiG assessed data subsequently submitted by the manufacturer
Now indication and hint of major added benefit for patients with metastatic prostate cancerEnzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic drug docetaxel.
Increased risk of prostate cancer in some men taking selenium and vitamin E supplements
A multi-center study led by Fred Hutchinson Cancer Research Center has found that high-dose supplementation with both the trace element selenium and vitamin E increase the risk of high-grade prostate cancer. But importantly, this risk depends upon a man's selenium status before taking the supplements.
Identifying men with advanced prostate cancer through genetic screening
Screening men with a family history of prostate cancer for a range of gene mutations can identify those who are at high risk of aggressive forms of the disease and in need of lifelong monitoring, a new study has shown.
Selenium and vitamin E supplements 'increase prostate cancer risk'
A new study recently published in the Journal of the National Cancer Institute suggests that taking high doses of selenium and vitamin E supplements may increase the risk of prostate cancer, depending on a man's selenium levels prior to taking the supplements.The research team, including first author Dr.